Geron Faces Investor Scrutiny Amid RYTELO Push and Trial Delays

FOSTER CITY, CA – February 23, 2026 – Geron Corporation is gearing up for a critical series of investor presentations in March, where its management team will face pointed questions about the company's commercial strategy and clinical pipeline. The commercial-stage biopharmaceutical firm announced it will present at the TD Cowen, Barclays, and Leerink Partners healthcare conferences, a standard roadshow that takes on heightened significance as the company navigates the complex launch of its blood cancer drug, RYTELO (imetelstat).

While the presentations offer a platform to showcase progress, they also place Geron under a microscope. Investors and analysts will be seeking reassurance on the sales trajectory of RYTELO, the timeline for its next major clinical trial readout, and the company's overall path to profitability following a recent strategic overhaul.

The RYTELO Report Card: A High-Stakes Commercial Launch

The central focus of investor inquiry will undoubtedly be the performance of RYTELO, Geron's first-in-class telomerase inhibitor approved in the U.S. and EU for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS). Since its U.S. launch in mid-2024, the drug's sales have painted a mixed picture. After a promising 24% quarter-over-quarter revenue increase to $49.0 million in the second quarter of 2025, sales dipped slightly to $47.2 million in the third quarter.

Company reports attribute the Q3 dip to demand fluctuations, even as the number of prescribing accounts grew. In response, and to align resources more effectively, Geron initiated a significant strategic restructuring in late 2025, which included reducing its workforce by approximately one-third. Management has framed this move as a way to streamline operations and intensify its commercial focus on physician education to drive earlier-line adoption of RYTELO.

Now, the pressure is on to demonstrate that this leaner strategy can deliver on the company’s ambitious 2026 net product revenue guidance of $220 million to $240 million. Achieving this target is crucial for validating the drug's market potential and building investor confidence. The upcoming commercialization in select European Union countries, set to begin this year with initial shipments already underway to Germany, represents a key potential growth driver that will be closely watched.

Data from the pivotal IMerge Phase 3 trial, which supported RYTELO's approval, continues to be a talking point. Recent analyses presented at the 2025 American Society of Hematology (ASH) meeting highlighted the durability of the treatment's effect, with 18% of patients achieving red blood cell transfusion independence for over a year. Geron's leadership will likely leverage this data at the conferences to reinforce the drug's clinical value proposition to a financial audience.

The High-Stakes Wait for Myelofibrosis Data

Beyond the immediate sales numbers for LR-MDS, Geron's long-term valuation is heavily tied to the success of imetelstat in other indications, most notably myelofibrosis (MF). The company’s pivotal Phase 3 IMpactMF trial is evaluating the drug in patients with MF who have relapsed after or are refractory to JAK inhibitor therapy—a population with significant unmet medical need.

This trial is designed to measure a gold-standard primary endpoint: overall survival (OS). Positive results could unlock a substantial new market and solidify imetelstat as a cornerstone therapy in hematologic malignancies. However, the timeline for this catalyst has become a point of contention for some investors. Geron has guided that the interim analysis for the trial, which completed enrollment of 320 patients in September 2025, is not expected until the second half of 2026. The final analysis is even further out, projected for the second half of 2028.

This extended timeline leaves a lengthy gap without a major clinical catalyst, a factor that has contributed to bearish sentiment. "The bull case hinges on a flawless RYTELO ramp-up and positive MF data, but the bears see flatlining sales and a long wait for the next value-creating event," one market analyst noted. Management will be expected to provide firm reassurance on the trial's progress and articulate the value proposition of its broader pipeline, which includes studies like IMproveMF, a Phase 1 trial combining imetelstat with ruxolitinib for frontline MF patients.

Balancing the Books on the Path to Profitability

Underpinning the commercial and clinical narratives is the company's financial health. With approximately $420 million in cash and marketable securities as of September 30, 2025, Geron has stated it can reach profitability without the need for additional financing. This projection is contingent on meeting its internal sales forecasts and maintaining disciplined spending.

The recent restructuring was a key part of this financial strategy. By reducing its workforce and streamlining operations, Geron has lowered its projected full-year 2026 operating expenses to a range of $230 million to $240 million. This cost management, combined with growing RYTELO revenue, forms the foundation of its path to self-sustainability. During the fireside chats and meetings, investors will probe the durability of these cost savings and the assumptions built into the company's cash runway calculations.

Navigating a Skeptical Market

The wide spectrum of analyst ratings—from "Strong Buy" to "Strong Sell"—and a broad range of price targets, from as low as $1.00 to a high of $9.00, illustrates the market's deep division over Geron's prospects. The company's stock, trading under $2.00, reflects this uncertainty.

The upcoming conferences in Boston and Miami are more than just a routine update; they are a critical opportunity for Geron's leadership to seize control of the narrative. They must convince a skeptical audience that the RYTELO commercial strategy is sound, that the long wait for myelofibrosis data will be worth it, and that the company is on a firm financial footing. The investment community will be watching closely to see if management can deliver a convincing performance that justifies their long-term vision and calms near-term anxieties.